Page last updated: 2024-11-05

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Cancer of Head

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Cancer of Head in 1 studies

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.

Research Excerpts

ExcerptRelevanceReference
"Head and neck squamous cell carcinoma (HNSCC) is an aggressive and often fatal disease."1.46Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells. ( Ben-Jonathan, N; Kumar, B; Kumar, P; Takiar, V; Tuttle, TR, 2017)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tuttle, TR1
Takiar, V1
Kumar, B1
Kumar, P1
Ben-Jonathan, N1

Other Studies

1 other study available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Cancer of Head

ArticleYear
Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells.
    Cancer letters, 2017, 03-28, Volume: 389

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; beta Catenin; Carcinoma, Squamous Cell

2017